By A Mystery Man Writer
A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and
Processes, Free Full-Text
Frontiers Towards Building a Quantitative Proteomics Toolbox in
Karmanos Cancer Institute on LinkedIn: #yourbestchance #onepride
Clinical Trial for Communication App About Cancer-Treatment Cost
IN THE NEWS: New treatments for metastatic breast cancer
Arquer Diagnostics' ADXBLADDER Undergoes U.S. Clinical Trials
Phenotypic Biomarkers in Precision Medicine
Combining Diagnostics & Therapeutics Pioneering Precision Medicine
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Biomarker development in the precision medicine era: lung cancer
Khalil CHOUCAIR, Medical Doctor, MD MSc
Importance of Quality of Life When Choosing Therapy for nmCRPC